Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).

Ohsang KwonMaryanne M SennaRodney SinclairTaisuke ItoYves DutroncChen-Yen LinGuanglei YuChiara ChiasseriniJill McCollamWen-Shuo WuBrett King

Published in: American journal of clinical dermatology (2023)

ClinicalTrials.gov NCT03570749 and NCT03899259. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata: Week-52 Results from BRAVE-AA1 and BRAVE-AA2.

Keyphrases

phase iii
open label
clinical trial
early onset
placebo controlled
double blind
randomized controlled trial
mesenchymal stem cells